GODREJAGRO Q1 FY27 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,852 Cr
verified against source
Revenue YoY
10%
reported change
EBITDA
Pending
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Godrej Agrovet delivered ₹2,852 crore in consolidated sales (+10% YoY) despite a challenging environment marked by delayed monsoon and geopolitical inflation. Animal Nutrition was the standout performer with 12.6% revenue growth and 15% cattle feed volume expansion, driven by strategic sourcing and operating leverage. Oil Palm maintained momentum with 28.9% revenue growth, though FFB volumes were flat due to a severe June rainfall deficit contrasting last year's early monsoon. Crop Care disappointed with 16.2% revenue decline as delayed kharif sowing impacted cotton herbicide volumes, though new launches Ashitaka and Takai captured 18-20% of Q1 sales. Aztec Life Sciences reached EBITDA break-even versus a ₹11 crore loss last year. Dairy faced margin pressure from elevated milk procurement prices but posted 11.4% revenue growth with value-added products rising to 49% of sales. Management targets double-digit growth for FY27 but deferred specific consolidated guidance to Q2-end pending clearer visibility on crop care recovery, which depends on monsoon normalization and cotton herbicide season performance in Q3.
Colored figures show movement against the previous available record.
Guidance to track
- Management remains confident of double-digit revenue growth for FY27 but deferred specific mid-teas guidance to Q2-end pending clearer crop care visibility. Q2 assessment will determine where double-digit lands within the range.
- Targeting 8-10% FFB volume growth annually over the 4-5 year LRP period, driven by 17,000 hectares annual area expansion, geographic diversification into Telangana and Northeast, and 50% of plantations in juvenile stage (0-4 years) approaching productive age.
- Annual capex guidance maintained at ₹300-350 crore, covering oil palm area expansion, integrated palm oil complex in Karnataka (nursery, CPO mill, seed garden, refinery), and specialty fats facility—slated for September rollout.
- Full-year revenue growth guidance upgraded from 20% to more than 20%, with Q1 at -8-9% being recovered in H2. CDMO salience expected at 50-52% of total revenue. EBITDA break-even achieved in Q1 versus ₹11 crore loss in Q1 FY26.
Risks flagged
- Analyst Hardik from ICICI Securities directly questioned why Godrej lagged peers despite similar monsoon impact. Management attributed underperformance to high concentration in cotton herbicide (40% of business) versus competitors with diversified portfolios.
- EBITDA margin in Oil Palm declined from 19% to 17% despite 18% realization increase, with management citing government formula-driven pricing pass-through to farmers and seasonal FFB volume phasing. Management expects recovery in Q2-Q3 peak seasons but provided no specific margin guidance.
- Milk procurement prices remain elevated and are expected to persist for 2-3 more quarters. Management passing through only 70% of price increases due to competitive constraints and consumer acquisition priorities. Combined with LPG/packaging inflation from Middle East tensions, profitability remains under pressure.
- Oil Palm FFB volumes were flat against a strong Q1 FY26 (early monsoon base). While management attributed this to weather, the demographic dividend and extension work partially offset the drought impact, making it unclear if volumes can reaccelerate without favorable monsoon timing.
Key quotes
- We want to get out of that [single-crop dependence]. So as part of that the first maize herbicide has got off to a rollicking start for us. We have rolled out Ashitaka fully in this season and I'm happy to share that we are in we have gone beyond our initial internal plans.
- The NPDS which we are investing behind we have done a very large scale expansion of new products under Yummy's nuggets product itself... There is going to be a new category which we believe has a huge potential over a period of years. It's a category creation job which is momos, frozen momos.
- CDPL business is undergoing a bit of a correction and transformation right now... We're very seriously looking at which are the markets which are profitable for us, which are the markets we have right to win and we are reconstituting our route to market completely and that's going to be roughly around an 18-month exercise.
Research modules